Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating CT1812 for mild to moderate Alzheimer's disease. The results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CT1812

Snippet

Sponsor: Cognition Therapeutics | Conditions: Mild to Moderate Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-08-11